* Kura Oncology Inc KURA.OQ KURA.O is expected to show
no
change in quarterly revenue when it reports results on May 2
for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Kura Oncology Inc is for
a
loss of 55 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.
* Wall Street's median 12-month price target for Kura
Oncology Inc
is $32.00, above its last closing price of $20.06.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.54 -0.55 -0.55 Met -0.1
Sep. 30 2023 -0.54 -0.55 -0.50 Beat 9
Jun. 30 2023 -0.55 -0.55 -0.53 Beat 3.6
Mar. 31 2023 -0.53 -0.54 -0.50 Beat 8.1
Dec. -0.57 -0.57 -0.49 Beat 14.3
31 2022
Sep. 30 2022 -0.55 -0.56 -0.53 Beat 5.7
Jun. 30 2022 -0.51 -0.52 -0.52 Met -0.9
Mar. 31 2022 -0.51 -0.52 -0.49 Beat 5.2
This summary was machine generated April 30 at 21:51 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)